Bizily Scott 4
4 · 4D Molecular Therapeutics, Inc. · Filed Oct 27, 2025
Insider Transaction Report
Form 4
Bizily Scott
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2025-10-24$6.49/sh+1,084$7,035→ 6,272 total - Sale
Common Stock
2025-10-24$12.00/sh−2,678$32,136→ 3,594 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-24−1,084→ 9,295 totalExercise: $6.49Exp: 2032-06-17→ Common Stock (1,084 underlying)
Footnotes (2)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
- [F2]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.